

# ACCP $\beta$ (H-7): sc-390344



The Power to Question

## BACKGROUND

Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system, which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. Exercise diminishes the activity of acetyl-CoA carboxylase in human muscle. ACC $\alpha$  (ACC1) is the rate-limiting enzyme in the biogenesis of long-chain fatty acids, and ACC $\beta$  (ACC2) is thought to control mitochondrial fatty acid oxidation. These two isoforms of ACC control the amount of fatty acids in the cells. ACC- $\beta$  is thought to control fatty acid oxidation by means of the ability of malonyl-CoA to inhibit carnitine-palmitoyl-CoA transferase I, the rate-limiting step in fatty acid uptake and oxidation by mitochondria. The gene encoding ACC $\beta$  maps to human chromosome 12q24.11 and encodes a mitochondrial protein expressed in heart and skeletal muscle. The catalytic core of ACC $\beta$  is homologous to that of the ACC $\alpha$ , except for an additional peptide of about 150 amino acids at the N terminus.

## REFERENCES

1. Ha, J., et al. 1996. Cloning of human acetyl-CoA carboxylase- $\beta$  and its unique features. *Proc. Natl. Acad. Sci. USA* 93: 11466-11470.
2. Kim, K.H. 1997. Regulation of mammalian acetyl-coenzyme A carboxylase. *Annu. Rev. Nutr.* 17: 77-99.
3. Dean, D., et al. 2000. Exercise diminishes the activity of acetyl-CoA carboxylase in human muscle. *Diabetes* 49: 1295-1300.
4. Abu-Elheiga, L., et al. 2000. The subcellular localization of acetyl-CoA carboxylase 2. *Proc. Natl. Acad. Sci. USA* 97: 1444-1449.

## CHROMOSOMAL LOCATION

Genetic locus: ACACB (human) mapping to 12q24.11; Acacb (mouse) mapping to 5 F.

## SOURCE

ACCP $\beta$  (H-7) is a mouse monoclonal antibody specific for an epitope mapping between amino acids 87-106 near the N-terminus of ACC $\beta$  of rat origin.

## PRODUCT

Each vial contains 200  $\mu$ g IgG $_{2b}$  kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

ACCP $\beta$  (H-7) is available conjugated to agarose (sc-390344 AC), 500  $\mu$ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-390344 HRP), 200  $\mu$ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-390344 PE), fluorescein (sc-390344 FITC), Alexa Fluor<sup>®</sup> 488 (sc-390344 AF488), Alexa Fluor<sup>®</sup> 546 (sc-390344 AF546), Alexa Fluor<sup>®</sup> 594 (sc-390344 AF594) or Alexa Fluor<sup>®</sup> 647 (sc-390344 AF647), 200  $\mu$ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor<sup>®</sup> 680 (sc-390344 AF680) or Alexa Fluor<sup>®</sup> 790 (sc-390344 AF790), 200  $\mu$ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Blocking peptide available for competition studies, sc-390344 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

Alexa Fluor<sup>®</sup> is a trademark of Molecular Probes, Inc., Oregon, USA

## APPLICATIONS


ACCP $\beta$  (H-7) is recommended for detection of ACC $\beta$  of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for ACC $\beta$  siRNA (h): sc-43597, ACC $\beta$  siRNA (m): sc-140800, ACC $\beta$  shRNA Plasmid (h): sc-43597-SH, ACC $\beta$  shRNA Plasmid (m): sc-140800-SH, ACC $\beta$  shRNA (h) Lentiviral Particles: sc-43597-V and ACC $\beta$  shRNA (m) Lentiviral Particles: sc-140800-V.


Molecular Weight of ACC $\beta$ : 275-280 kDa.

Positive Controls: rat liver extract: sc-2395 or PC-12 cell lysate: sc-2250.

## DATA



ACCP $\beta$  (H-7): sc-390344. Western blot analysis of ACC $\beta$  expression in rat liver tissue extract.



ACCP $\beta$  (H-7): sc-390344. Western blot analysis of ACC $\beta$  expression in PC-12 whole cell lysate.

## SELECT PRODUCT CITATIONS

1. Qi, N., et al. 2017. Therapeutic hexapeptide (PGPIP<sub>N</sub>) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress. *Oncotarget* 8: 88079-88093.
2. Seidu, T., et al. 2021. DHT causes liver steatosis via transcriptional regulation of SCAP in normal weight female mice. *J. Endocrinol.* 250: 49-65.
3. Chen, J., et al. 2022. PFKP alleviates glucose starvation-induced metabolic stress in lung cancer cells via AMPK-ACC2 dependent fatty acid oxidation. *Cell Discov.* 8: 52.
4. Sudharma, A.A., et al. 2023. Atrophic remodeling of the heart during Vitamin D deficiency and insufficiency in a rat model. *J. Nutr. Biochem.* 119: 109382.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.